Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Has results × DOXO-EMCH × Clear all
NCT02200757 2024-06-25

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Completed
135 enrolled 11 charts
Thoracic

Small Cell Lung Carcinoma

NCT01580397 2024-06-06

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

ImmunityBio, Inc.

Phase 2 Completed
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01514188 2024-05-29

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

ImmunityBio, Inc.

Phase 2 Completed
126 enrolled 13 charts
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT02014844 2024-05-29

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

ImmunityBio, Inc.

Phase 2 Completed
28 enrolled 10 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡